PubMed Health⌕ Search

Biomedical subjects

F Milazzotto

Publications and source records attributed to F Milazzotto.

At least 37 records · Page 2Linked to original sources
PubMed1989

[Kinetics of intravenously administered flecainide in patients with acute myocardial infarct].

Flecainide (F) is a new antiarrhythmic agent recently introduced into clinical practice. The above study was aimed at evaluating its intravenous (iv) pharmacokinetics in patients (pts) with acute myocardial infarction (AMI) on 1st and 2nd day, complicated by complex ventricular premature beats (VPBs). 2 mg/kg F was given iv as bolus injection, followed by 300 mg/24 hrs iv infusion. Plasma F values were evaluated by HPLC. Plasma F levels increased progressively, in a non uniform but predictable manner: in pts with large AMI and cardiac failure, F plasma levels, although remaining within the therapeutic range, were greatly increased after the 2nd hour (P less than 0.05) in comparison with pts without cardiac insufficiency. Negative side effects, both cardiac and extracardiac, were not observed: F appeared a handy and effective agent in post-AMI arrhythmias, especially when plasma drug levels are controlled; plasma F level monitoring is anyway recommended in pts with cardiac failure, owing to the wide interindividual variations.

Adult↗
PubMed1989

Use of defibrotide in the treatment of acute myocardial infarction.

The results of this preliminary clinical trial confirm the thrombolytic effect of defibrotide demonstrated in preclinical models; demonstrate the positive influence of the product on the natural history of early AMI; suggest that the optimal dosage range should include not less than 1.6 gm of defibrotide during the first hour of treatment; and justify further commitment in the study of defibrotide also beyond the scope of treating AMI.

Dose-Response Relationship, Drug↗
PubMed1985

[Efficacy of oral nitroglycerin in the therapy of exertion angina].

A sample of 14 patients suffering from stable effort angina has been examined by means of exercise ECG test, in order to evaluate the efficacy, the onset of action and duration of effect of buccal nitroglycerin in the treatment of effort angina. The optimal dose of buccal NTG was predetermined for each patient through the analysis of heart rate changes (increase of at least 10 beats/min) and/or of blood pressure modifications (decrease of at least 10 mmHg). By applying a randomized double-blind design, the variations observed during exercise ECG tests after 20 minutes and 4 hours from the administration of buccal NTG (at the given dosage) or of placebo, have been evaluated. The following variables have been analyzed: heart rate, blood pressure, double product, time of onset of angina and/or of ST depression, amount of ST depression, duration of exercise test and maximum work-load. No significant changes have been observed for heart rate, blood pressure and double product both at the maximum effort and at the same level of effort as in the basal test. For each of the remaining variables a significant difference has been shown in favour of buccal NTG as compared to placebo, both after 20 min. and 4 hs. More in detail, the duration of the exercise test has been 6.14 +/- 2.77 mins on buccal NTG and 4.42 +/- 2.08 mins on placebo (+ 38%; p less than 0.05) after 20 mins and 6.40 +/- 3.19 on buccal NTG and 5.15 +/- 2.73 on placebo, after 4hs (+ 24%; p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗
PubMed1984

[Combinations of some anti-arrhythmia drugs].

The need to treat severe and repetitive arrhythmias which are often resistant to treatment with single different drugs has led to an increasing interest towards associations of antiarrhythmic drugs. The advantages of this associations could be: enhancing effect of different pharmacological properties, synergism, reduction of doses and side-effects. The risks are: induction or aggravation of excitability and conduction disturbances, impairment of contractility, hypotension, interaction with digoxin. This study describes our experience in using associations of antiarrhythmic drugs of different classes (IA + II, IA + III, IB + III) or of the same class (IA). We also report our preliminary results with the use of Propafenon-Amiodarone association in the acute treatment of electrophysiologically induced ventricular tachycardias and in the chronic treatment of repetitive and symptomatic ventricular tachycardias. Our experience demonstrates that the association of antiarrhythmic drugs is effective in the treatment of severe and repetitive arrhythmias only if the patients are carefully selected and the risks of unwelcome electrophysiological actions and side-effects are taken into account.

Adrenergic beta-Antagonists↗
PubMed1982

[Disorders of formation and conduction of the cardiac impulse in hypertrophic and congestive primary myocardiopathy].

Little information is available regarding cardiac automatism and conduction disturbances in patients affected by congestive (CCM) or hypertrophic (HCM) cardiomyopathies. For this reason 29 patients with HCM (10 cases) and CCM (19 cases) and disturbances of sinus node automaticity or AV conduction underwent an electrophysiologic study. Eight patients affected by HCM were also submitted to cardiac catheterization. Sinus node function was normal in each of the HCM patients, and impaired in 6 of the 19 CCM patients. The intra-atrial conduction was prolonged in only one CCM case. One HCM and 2 CCM patients showed an impaired intranodal AV conduction. Thirteen patients (44%) showed a prolonged HV interval (3 HCM and 10 CCM patients). No calcific deposits on the aortic valve were discovered by X ray stratigraphic examination in any of the patients. In 6 cases a progression of the conduction disturbances was observed. Ventricular pre-excitation was present in 4 patients (13%).

Adolescent↗